Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project
Introduction
Apolipoprotein (apo) E is an important component of plasma lipoproteins and influences lipoprotein metabolism through its action as a receptor ligand. Other important roles of apo E include immunomodulation and nerve regeneration. Apo E is polymorphic with three common alleles: ε2, ε3 and ε4 [1]. More recently polymorphisms in the promoter region have been described [2], [3]. The serum apo E concentration and cholesterol concentration are in part determined by the common apo E polymorphism; thus the ε2 allele is associated with lower serum cholesterol and higher apo E concentration, whereas the ε4 allele is associated with a high serum cholesterol and low apo E concentration [4]. A number of studies [5], [6] have demonstrated that the ε4 allele is associated with an increased risk of coronary artery disease (CAD). It is unclear whether this effect is mediated through the effect of the apo E genotype on lipids or through other mechanisms [7]. Furthermore, the different rates of CAD observed in European countries may partly been explained by the prevalence of apo E genotypes. The role of the apo E serum concentration as a risk factor for CAD has not been investigated.
During recent years several studies have demonstrated that apo E genotype is a determinant of susceptibility to Alzheimer's disease (AD) with ε4 homozygotes at increased risk (for review see [1]). This finding has provided important clues to the pathogenesis of AD. The role of the apo E serum concentration as a risk factor for AD has been studied but the results have been controversial [8], [9]. A prerequisite for the proper investigation of serum apo E concentrations as a risk marker is an understanding of the factors determining serum apo E concentration in health and the establishment of serum reference values
The ApoEurope Project, supported by the European Community, consists of three parts: part I, epidemiology of apo E concentration; part II, role of apo E in cardiovascular disease; part III, role of apo E in Alzheimer's disease. The specific objectives of this paper (part I of ApoEurope) are: (a), to describe the distribution of the serum apo E concentration across different European populations; (b), to study some factors affecting interindividual variation in serum apo E concentration: apo E genotype, age, sex, and geographical area; and (c), to provide apo E genotype related values for serum apo E concentration in four European regions. For these purposes, six research units were selected for collaboration.
Section snippets
Geographical distribution of the sampling locations
Subjects were selected in different geographic areas of Europe for participation in the ApoEurope Project (Part I). In four centres existing databases were used and in two centres new data were collected. Six centres participated: Crete (Greece); Helsinki (Finland); Belfast (Northern Ireland); Nancy (France); Lisbon (Portugal); and Barcelona (Spain). Four European regions were individualized: (a), North (Finland and Northern Ireland); (b), Middle (France); (c), South (Portugal and Spain); and
Population description
The population sample stratified by age, sex, and centre, is presented in Table 1. The contribution of each centre to the total population sample was 7.6% in Greece, about 9–10% in Portugal and Northern Ireland, and 15% in Spain. It reached 28% in France and 30% in Finland. Forty-seven point five percent of all young men, 25–34 years old, came from the Belfast cohort; a majority of males and females 35–44 years old, came from the French cohort (representing 50.5 and 54.3%); 52–60% of the
Discussion
The measurement of serum apo E concentration is, at present, rarely used in clinical chemistry as compared to the use of apo AI and B determinations. The apo E concentration is determined in part by the genetic variation at the apo E locus; however, a large amount of variability remains unexplained by this genetic factor, suggesting that other genetic and environmental components are major determinants of serum apo E concentration. This paper deals with the study of the influence of the apo E
Acknowledgments
We are grateful to all the participants for their contribution in recruitment and the collection of data of the ApoEurope Project. Special thanks to all subjects who made this study possible. This work was supported by the Région Lorraine, Daiichi Pure Chemicals and, by the European Community: contract no. BMH4-1543 (DG 126SSMA) and contract S.M.&T: MAT1-CT94-0046.
References (50)
- et al.
The −491 A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known Apo E polymorphism
Neurosci. Lett.
(1998) - et al.
Modulation of plasma triglyceride levels by apo E phenotype: a meta-analysis
J. Lipid. Res.
(1992) - et al.
Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study
Neurosci. Lett.
(1998) - et al.
Increased plasma apolipoprotein E (apo E) levels in Alzheimer's disease
Neurosci. Lett.
(1997) - et al.
Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial
Am. J. Clin. Nutr.
(1998) - et al.
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
J. Lipid Res.
(1990) - et al.
A rapid micromethod for apolipoprotein E phenotyping directly in serum
J. Lipid Res.
(1987) - et al.
Apolipoprotein E polymorphism in middle-aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins
Atherosclerosis
(1996) - et al.
Levels of lipids, lipoproteins and apolipoproteins in a defined population
Mayo Clin. Proc.
(1991) - et al.
Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal
Clin. Chim. Acta
(1996)
Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study
Arteriosclerosis
Apolipoprotein (apo) E genotype and apo E concentration determine binding of normal very low density lipoproteins to Hep G2 cell surface receptors
J. Lipid Res.
Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis
Am. J. Hum. Genet.
Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease
Neurosci. Lett.
Apolipoprotein E: An important gene and protein to be followed in laboratory medicine
Clin. Chem.
Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations
Clin. Chem.
Apolipoprotein E polymorphism predicts death from Coronary Heart Disease in a longitudinal study of elderly Finnish men
Circulation
Genotypes with the apolipoprotein ε-4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men aged 65–84 years
Hum. Genet.
Haemostatic factors and lipoprotein (a) in three geographical areas in Finland: the Finrisk haemostasis study
J. Cardiovasc. Risk
Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas Cohort
Clin. Chem. Lab. Med.
Recruitment methods and differences in early, late and non-respondents in the first MONICA-Catalonia population survey
Rev. Epidemiol. Santé Publ.
WHO MONICA Project: risk factors
Int. J. Epidemiol.
Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- sex-related differences
Clin. Chim. Acta
Cited by (134)
Apolipoprotein E O-glycosylation is associated with amyloid plaques and APOE genotype
2023, Analytical BiochemistryA Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward
2019, NeuronCitation Excerpt :Ultimately, the goal would be to have reliable, reproducible, and isoform-specific assays, so that, in a person with the APOE (3/4) genotype, one could measure the amount of plasma or CSF APOE3 and APOE4, rather than just the total amount of APOE. Bearing these caveats in mind, several large studies have now shown that plasma APOE levels vary, consistently, as a function of APOE genotype (Corsetti et al., 2016; Cruchaga et al., 2012; Khan et al., 2013; Rasmussen et al., 2015; Schiele et al., 2000). From APOE2 to APOE3 to APOE4, there tends to be a linear decline in APOE levels.
Apolipoproteins C-II and C-III as nutritional markers unaffected by inflammation
2018, Clinica Chimica ActaCitation Excerpt :Another confounding factor is ApoE phenotype, which is a common determinant of LDL-C concentrations in the general population. E4 carriers have high LDL-C concentrations while E2 carriers have low LDL-C concentrations [35–38]. Additionally, the effect of fatty acids on TC concentration varies according to fatty acid species or ApoE phenotype [39].